Skip to main content
CVRX
NASDAQ Industrial Applications And Services

CVRx Reports Strong Q1 2026 Results, Raises Gross Margin Guidance, and Advances Key Clinical Trial

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Medical Device Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$6.9
Mkt Cap
$182.902M
52W Low
$4.299
52W High
$11.3
52W Position info
60% above low
Off High info
39% below high
Rel. Volume info
1.2× avg
Market data snapshot near publication time

CVRX sits 60% above its 52-week low of $4.299.

Summary

CVRx reported robust first-quarter 2026 financial results with 20% revenue growth and improved gross margins, while also raising its full-year gross margin guidance and announcing the first patient enrollment in its pivotal BENEFIT-HF clinical trial.


Key Events · Earnings and Guidance · CVRX

  • Strong Q1 2026 Financial Results

    Total revenue increased 20% year-over-year to $14.8 million, with U.S. revenue up 22%. Gross margin improved to 87% from 84% in the prior year, and net loss narrowed to $13.1 million.

  • Raised Full-Year Gross Margin Guidance

    The company updated its full-year 2026 gross margin guidance range to 85%-87%, an increase from the prior 84%-86% range, while maintaining revenue and operating expense guidance.

  • BENEFIT-HF Clinical Trial Progress

    CVRx announced the first site activation and patient enrollment in its BENEFIT-HF clinical trial, a landmark study that could potentially triple the indicated patient population for its Barostim therapy.


Analysis · CVRX · Industrial Applications And Services

This 8-K confirms the strong preliminary first-quarter 2026 results previously announced, providing full financial details. The company reported significant revenue growth and improved gross margins, alongside a positive update to its full-year gross margin guidance. Progress in the BENEFIT-HF clinical trial, which could substantially expand the addressable market for Barostim, adds a long-term growth driver.

How filings like this one have moved

In the 30 days to Nov 15, 2026, 48.2% of the 1980 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.20%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, CVRX was trading at $6.90 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $182.9M. The 52-week trading range was $4.30 to $11.30. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

CVRX - Latest Insights

CVRX
Nov 05, 2026, 4:17 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $1.47
Real-time Price: $0.5839 info
Change: -$0.8861 (-60%) info
Market Cap: $16.615M info
CVRX
Nov 05, 2026, 4:10 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $1.47
Real-time Price: $0.5839 info
Change: -$0.8861 (-60%) info
Market Cap: $16.615M info
CVRX
Nov 05, 2026, 4:05 PM EST
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $1.47
Real-time Price: $0.5839 info
Change: -$0.8861 (-60%) info
Market Cap: $16.615M info
CVRX
Oct 02, 2026, 9:30 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
8
Price at Filing: $1.53
Real-time Price: $0.5839 info
Change: -$0.9461 (-62%) info
Market Cap: $16.615M info
CVRX
Sep 21, 2026, 4:13 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $2.97
Real-time Price: $0.5839 info
Change: -$2.39 (-80%) info
Market Cap: $16.615M info